AR064002A1 - SUBSTITUTED KINAZOLINS - Google Patents
SUBSTITUTED KINAZOLINSInfo
- Publication number
- AR064002A1 AR064002A1 ARP070105272A ARP070105272A AR064002A1 AR 064002 A1 AR064002 A1 AR 064002A1 AR P070105272 A ARP070105272 A AR P070105272A AR P070105272 A ARP070105272 A AR P070105272A AR 064002 A1 AR064002 A1 AR 064002A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- hydrogen
- bromine
- iodine
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos de la presente actuan por inhibicion de la megacariocitopoiesis y en consecuencia la formacion de plaquetas sanguíneas. Reivindicacion 1: Un compuesto de la formula (1) o una de sus sales o solvatos farmacéuticamente aceptables, caracterizado porque R1, R2, R3 y R4 independientemente representan hidrogeno o un grupo bloqueador con funcion de prevencion de la reaccion metabolica en la posicion de sustitucion 3; o en donde R1 y R2, y/o R3 y R4 junto con el carbono al que están adosados forman un grupo bloqueador que funciona para prevenir en forma directa o indirecta las reacciones metabolicas en la posicion 3, en donde el resto de los grupos R1 a R4 son hidrogeno; R5 se selecciona del grupo que comprende: fluor cloro, bromo y yodo; R6 se selecciona del grupo que comprende: fluor cloro, bromo y yodo; R7 y R8 son seleccionados independientemente del grupo que comprende: H; halo; ciano; alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, y haloalcoxi C1-6; y R9 es H, alquilo C1-6, o un ion metálico de Grupo I; siempre que R1, R2, R3 y R4 no sean todos hidrogeno, o que cuando uno de R1 y R2 es metilo y R3 y R4 son hidrogeno, entonces el otro de R1 y R2 no es hidrogeno.The compounds of the present act by inhibition of megakaryocytopoiesis and consequently the formation of blood platelets. Claim 1: A compound of the formula (1) or a pharmaceutically acceptable salt or solvate thereof, characterized in that R1, R2, R3 and R4 independently represent hydrogen or a blocking group with function of preventing the metabolic reaction in the substitution position 3; or where R1 and R2, and / or R3 and R4 together with the carbon to which they are attached form a blocking group that works to prevent directly or indirectly the metabolic reactions in position 3, where the rest of the R1 groups to R4 are hydrogen; R5 is selected from the group comprising: chlorine fluorine, bromine and iodine; R6 is selected from the group comprising: chlorine fluorine, bromine and iodine; R7 and R8 are independently selected from the group comprising: H; halo; cyano; C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C1-6 haloalkoxy; and R9 is H, C1-6 alkyl, or a Group I metal ion; provided that R1, R2, R3 and R4 are not all hydrogen, or when one of R1 and R2 is methyl and R3 and R4 are hydrogen, then the other of R1 and R2 is not hydrogen.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0623750.7A GB0623750D0 (en) | 2006-11-28 | 2006-11-28 | Substituted quinazolines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064002A1 true AR064002A1 (en) | 2009-03-04 |
Family
ID=37671460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105272A AR064002A1 (en) | 2006-11-28 | 2007-11-28 | SUBSTITUTED KINAZOLINS |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2099802A2 (en) |
| JP (1) | JP2010511030A (en) |
| KR (1) | KR20090094268A (en) |
| CN (1) | CN101558071B (en) |
| AR (1) | AR064002A1 (en) |
| AU (1) | AU2007327047B2 (en) |
| BR (1) | BRPI0719570A2 (en) |
| CA (1) | CA2670123A1 (en) |
| EA (1) | EA018259B1 (en) |
| GB (1) | GB0623750D0 (en) |
| IL (1) | IL198809A0 (en) |
| MX (1) | MX2009005579A (en) |
| TW (1) | TW200838537A (en) |
| WO (1) | WO2008065444A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8304420B2 (en) | 2006-11-28 | 2012-11-06 | Shire Llc | Substituted quinazolines for reducing platelet count |
| GB0808944D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substituted quinazolines |
| GB2462022B (en) * | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof |
| GB0822970D0 (en) * | 2008-12-17 | 2009-01-21 | Shire Llc | Process for the preparation of anagrelide and analogues |
| GB201004495D0 (en) | 2010-03-18 | 2010-05-05 | Shire Llc | Subtituted quinazolines |
| GB201017783D0 (en) | 2010-10-21 | 2010-12-01 | Shire Llc | Process for the preparation of anagrelide and analogues thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7807507A (en) * | 1977-07-25 | 1979-01-29 | Hoffmann La Roche | TRICYCLICAL CONNECTIONS. |
| CA1131631A (en) * | 1979-06-20 | 1982-09-14 | Madhukar S. Chodnekar | Quinazoline derivatives and pharmaceutical preparations |
| ZA803535B (en) * | 1979-06-20 | 1981-06-24 | Hoffmann La Roche | Novel quinazoline derivatives and pharmaceutical preparations |
| US20040209907A1 (en) * | 2003-01-23 | 2004-10-21 | Richard Franklin | Formulation and methods for the treatment of thrombocythemia |
| US20060030574A1 (en) * | 2004-08-04 | 2006-02-09 | Shire Holdings Ag | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors |
| US7700608B2 (en) * | 2004-08-04 | 2010-04-20 | Shire Holdings Ag | Quinazoline derivatives and their use in the treatment of thrombocythemia |
-
2006
- 2006-11-28 GB GBGB0623750.7A patent/GB0623750D0/en not_active Ceased
-
2007
- 2007-11-19 MX MX2009005579A patent/MX2009005579A/en unknown
- 2007-11-19 AU AU2007327047A patent/AU2007327047B2/en not_active Expired - Fee Related
- 2007-11-19 BR BRPI0719570-2A patent/BRPI0719570A2/en not_active IP Right Cessation
- 2007-11-19 CN CN2007800442429A patent/CN101558071B/en not_active Expired - Fee Related
- 2007-11-19 JP JP2009538792A patent/JP2010511030A/en active Pending
- 2007-11-19 WO PCT/GB2007/050697 patent/WO2008065444A2/en active Application Filing
- 2007-11-19 EP EP07824909A patent/EP2099802A2/en not_active Withdrawn
- 2007-11-19 CA CA002670123A patent/CA2670123A1/en not_active Abandoned
- 2007-11-19 EA EA200900740A patent/EA018259B1/en not_active IP Right Cessation
- 2007-11-19 KR KR1020097011682A patent/KR20090094268A/en not_active Application Discontinuation
- 2007-11-27 TW TW096145020A patent/TW200838537A/en unknown
- 2007-11-28 AR ARP070105272A patent/AR064002A1/en unknown
-
2009
- 2009-05-19 IL IL198809A patent/IL198809A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090094268A (en) | 2009-09-04 |
| AU2007327047A1 (en) | 2008-06-05 |
| EA200900740A1 (en) | 2010-02-26 |
| WO2008065444A2 (en) | 2008-06-05 |
| GB0623750D0 (en) | 2007-01-10 |
| JP2010511030A (en) | 2010-04-08 |
| CN101558071A (en) | 2009-10-14 |
| IL198809A0 (en) | 2010-02-17 |
| EA018259B1 (en) | 2013-06-28 |
| WO2008065444B1 (en) | 2008-10-09 |
| BRPI0719570A2 (en) | 2013-12-10 |
| TW200838537A (en) | 2008-10-01 |
| WO2008065444A3 (en) | 2008-07-31 |
| CN101558071B (en) | 2013-04-24 |
| MX2009005579A (en) | 2009-08-12 |
| CA2670123A1 (en) | 2008-06-05 |
| EP2099802A2 (en) | 2009-09-16 |
| AU2007327047B2 (en) | 2012-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064002A1 (en) | SUBSTITUTED KINAZOLINS | |
| CO6382182A2 (en) | PROCESS FOR THE PREPARATION OF BENZONORBORNEN-5-IL-AMIDAS OF PIRAZOLIL-4-CARBOXYL ACID. | |
| AR064452A1 (en) | DERIVATIVES OF 1,2,4 OXADIAZOL-INDOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND USES IN DISORDERS ASSOCIATED WITH S1P1 RECEPTORS. | |
| PE20130375A1 (en) | TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINE COMPOUNDS, C-MET INHIBITORS AND COMPOSITIONS THEREOF | |
| AR073892A1 (en) | SGLT INHIBITORS PREPARATION PROCESS | |
| PE20121047A1 (en) | THIAZOLYLPIPERIDINE DERIVATIVES AS FUNGICIDES | |
| AR071385A1 (en) | COMPOUNDS OF 2-IMINO-3-METHYL PIRROLOPIRIMIDINONE REPLACED WITH THIOPHENYLL, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USE OF THE SAME FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH THE BETA AMYLOID PROTEIN, SUCH AS ALZHEIMAS DE OMOSTER DE OMOS. | |
| CY1111308T1 (en) | PREPARATION OF ESLICARVASPINE AND RELATED COMPOUNDS WITH ASymmetric Hydrogenation | |
| AR063464A1 (en) | PROCEDURE TO PREPARE DIFLUOROMETILPIRAZOLIL CARBOXYLATES | |
| RU2014128826A (en) | MALONIC ACID DISSOLES AND METHOD FOR PRODUCING MALONYDIGALOGENIDES | |
| AR051995A1 (en) | TIENO-PYRIDINE DERIVATIVES AS GABA -B ALLOSTERIC INTENSIFIERS | |
| AR059590A1 (en) | HYDANTOIN-BASED QUINASE INHIBITORS | |
| PE20071326A1 (en) | VIRAL POLYMERASE INHIBITORS | |
| CO6331462A2 (en) | PIRROL FENIL COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME WITH GLUCOQUINASE ACTIVATING ACTIVITY | |
| ES2529233T3 (en) | Tetrazole compounds as calcium channel blockers | |
| AR054341A1 (en) | SYNERGIC COMBINATIONS OF FUNGICIDAL ACTIVE COMPOUNDS | |
| AR063449A1 (en) | CHEMICAL PROCESS FOR QUINAZOLINE DERIVATIVES, INTERMEDIARIES | |
| AR084913A1 (en) | DERIVATIVES OF ARIL-BENZOCICLOALQUIL-AMIDA | |
| RS52900B (en) | Benzoylpyrazole compounds, process for their production and herbicides containing them | |
| CO6150150A2 (en) | DERIVATIVES OF 7-ALQUINIL-1,8-NAFTIRIDONAS ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| CO2020001326A2 (en) | New heterocyclic compounds as cdk8 / 19 inhibitors | |
| CO6190578A2 (en) | NEWS DERIVED FROM IMIDAZOL | |
| PE20151977A1 (en) | NEW PURINE DERIVATIVES | |
| CO5700717A2 (en) | USEFUL COUPLING REACTIONS IN THE PREPARATION OF DERIVATIVES OF (1H-TETRAZOL-5-IL) -BIFENYL | |
| PE20141391A1 (en) | COMBINATION THAT INCLUDES A COMPOUND WITH ANTIVIRAL ACTIVITY AND A THERAPEUTIC AGENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |